Anthony Gristina1432 Church Hill Pl, Reston, VA 20194

5591441, Jan 7, 1997

Feb 16, 1994

8/197340

Anthony G. Gristina - Reston VA
Quentin N. Myrvik - Caswell Beach NC

Medical Sciences Research Institute - Herndon VA

A61K 914
A61F 202
A61L 904

424401

A non-specific host immune cell augmentation composition for enhanced microorganism killing utilizes any phagocytosable, biocompatible particle to prime macrophages for enhanced oxidative response and bacterial killing. Patients can have the benefits of primed macrophages in one to four days, and experiments have demonstrated over a 100-fold increase in oxidative potential within this time period. The oxidative response and killing potential is non-immunospecific, meaning not one organism, not a vaccine, and broadly applicable simultaneously to bacteria and viruses as well as tumor cells. The effects have been demonstrated to have a seven day duration to have a seven day duration indicating non-tissue toxic residual effects and potential for repeated use at monthly intervals.

5817312, Oct 6, 1998

Oct 14, 1997

8/949862

Anthony G. Gristina - Reston VA
Girish Giridhar - Manassas Park VA

Medical Sciences Research Institute - Herndon VA

A61K 3940
A01N 2502
A61L 904
C07K 1600

4241641

The direct, concentrated local delivery of antibodies, and pooled human immunoglobulins in particular, to tissue surfaces (e. g. , wounds, burns, etc. ), and biomaterial implant surfaces significantly decreases the rate of infection at those sites and enhances healing. The immunoglobulins serve to opsonize circulating infectants for phagocytosis and killing, prior to microbial adhesion and biofilm formation, and neutralize bacterial toxins. The treatment methodology results in reduced inflammation, reduced complement and tissue damage, and reduced rejection of biomaterials and transplants.

5505945, Apr 9, 1996

Aug 25, 1994

8/295482

Anthony G. Gristina - Reston VA
Quentin N. Myrvik - Caswell Beach NC

Medical Sciences Research Institute - Herndon VA

A61K 3940
A61K 39085
A61K 3909
A61K 39104

4241641

Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, Coagulase Negative Staphylococci Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp. , etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to viral or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release. The immunoglobulins in the composition can be immobilized on a biocompatible material such as collagen, fibrin, hyaluronan, biodegradable polymers, and fragments thereof, which will be placed in-situ at the wound, surgical or burn site. In addition, the immunoglobulins in the composition may be coated on the body contacting surface of an implantable device such as a catheter, contact lens or total joint.

5681565, Oct 28, 1997

Jan 24, 1996

8/590880

Anthony G. Gristina - Reston VA
Girish Giridhar - Manassas Park VA

Medical Sciences Research Institute - Herndon VA

A61K 3940
A61K 39085
A61K 3909
A61K 39104

4241641

The direct, concentrated local delivery of antibodies, and pooled human immunoglobulins in particular, to tissue surfaces (e. g. , wounds, burns, etc. ), and biomaterial implant surfaces significantly decreases the rate of infection at those sites and enhances healing. The immunoglobulins serve to opsonize circulating infectants for phagocytosis and killing, prior to microbial adhesion and biofilm formation, and neutralize bacterial toxins. The treatment methodology results in reduced inflammation, reduced complement and tissue damage, and reduced rejection of biomaterials and transplants.

5292513, Mar 8, 1994

May 18, 1992

7/885301

Anthony G. Gristina - Reston VA
Quentin N. Myrvik - Caswell Beach NC

A61L 904
A61K 914
A61K 4505
C12Q 118

424401

A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable, biocompatible particle to prime macrophages for enhanced oxidative response and bacterial killing. Patients can have the benefits of primed macrophages in one to four days, and experiments have demonstrated over a 100-fold increase in oxidative potential within this time period. The oxidative response and killing potential is non-immunospecific, meaning not one organism, not a vaccine, and broadly applicable simultaneously to bacteria and viruses as well as tumor cells. The effects have been demonstrated to have a seven day duration indicating non-tissue toxic residual effects and potential for repeated use at monthly intervals.

5718899, Feb 17, 1998

Feb 29, 1996

8/608817

Anthony George Gristina - Reston VA
Quentin Newell Myrvik - Caswell Beach NC

A16K 3940
A16K 39085
A16K 3909
A16K 39104

4241641

Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue at times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, CNS, Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp. , etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to vital or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release. The immunoglobulins in the composition can be immobilized on a biocompatible material such as collagen, fibrin, hyaluronan, biodegradable polymers, and fragments thereof, which will be placed in-situ at the wound, surgical or burn site. In addition, the immunoglobulins in the composition may be coated on the body contacting surface of an implantable device such as a catheter, contact lens or total joint.

5770234, Jun 23, 1998

Dec 13, 1996

8/764585

Anthony G. Gristina - Reston VA
Girish Giridhar - Manassas Park VA

Medical Sciences Research Institute - Herndon VA

A61K 914
A61F 202
A61L 904

424501

A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable particle to prime macrophages for enhanced oxidative response and bacterial killing. The phagocytosable particles should be administered at the time of exposure to contagion, or one day prior to or up to 6-12 hours after exposure. Administration can be performed by any suitable means which will bring the particles quickly into contact with the blood stream where they will encounter phagocytes and cause priming of the patient's macrophages. The augmentation technique provides for non-specific cellular immunity from a wide range of contagion.

5707627, Jan 13, 1998

Feb 29, 1996

8/609912

Anthony George Gristina - Reston VA
Quentin Newell Myrvik - Caswell Beach NC

A61K 3940
A61K 39085
A61K 3909
A61K 39104

424 641

Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue at times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, CNS, Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp. , etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to viral or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release. The immunoglobulins in the composition can be immobilized on a biocompatible material such as collagen, fibrin, hyaluronan, biodegradable polymers, and fragments thereof, which will be placed in-situ at the wound, surgical or burn site. In addition, the immunoglobulins in the composition may be coated on the body contacting surface of an implantable device such as a catheter, contact lens or total joint.